IL317722A - Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide - Google Patents

Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide

Info

Publication number
IL317722A
IL317722A IL317722A IL31772224A IL317722A IL 317722 A IL317722 A IL 317722A IL 317722 A IL317722 A IL 317722A IL 31772224 A IL31772224 A IL 31772224A IL 317722 A IL317722 A IL 317722A
Authority
IL
Israel
Prior art keywords
cyanothiazolidin
morpholinoquinoline
oxoethyl
carboxamide
solid
Prior art date
Application number
IL317722A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL317722A publication Critical patent/IL317722A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL317722A 2022-06-21 2023-06-20 Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide IL317722A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263366696P 2022-06-21 2022-06-21
PCT/EP2023/066559 WO2023247487A1 (en) 2022-06-21 2023-06-20 Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide

Publications (1)

Publication Number Publication Date
IL317722A true IL317722A (en) 2025-02-01

Family

ID=87047690

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317722A IL317722A (en) 2022-06-21 2023-06-20 Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide

Country Status (12)

Country Link
US (1) US20250368637A1 (en)
EP (1) EP4543877A1 (en)
JP (1) JP2025521304A (en)
KR (1) KR20250027736A (en)
CN (2) CN120554349A (en)
AU (1) AU2023288645A1 (en)
CA (1) CA3260370A1 (en)
CL (1) CL2024003894A1 (en)
IL (1) IL317722A (en)
MA (1) MA71234A (en)
MX (1) MX2024015644A (en)
WO (1) WO2023247487A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119802A1 (en) 2024-12-02 2026-06-11 Astrazeneca Ab Dosing regimen for the treatment of fap-mediated conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CN113811529A (en) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 fibroblast-activated protein inhibitor
UY39569A (en) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-CYANOTHIAZOLIDIN-3-IL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES

Also Published As

Publication number Publication date
WO2023247487A1 (en) 2023-12-28
US20250368637A1 (en) 2025-12-04
EP4543877A1 (en) 2025-04-30
JP2025521304A (en) 2025-07-08
KR20250027736A (en) 2025-02-27
MA71234A (en) 2025-04-30
CN120554349A (en) 2025-08-29
MX2024015644A (en) 2025-02-10
CN119585266A (en) 2025-03-07
AU2023288645A1 (en) 2025-02-13
CA3260370A1 (en) 2023-12-28
CL2024003894A1 (en) 2025-02-07

Similar Documents

Publication Publication Date Title
MA54526A (en) NEW POLYMORPHIC FORMS OF A TGFBeta INHIBITOR
EP3947361A4 (en) SALT AND CRYSTALLINE FORM OF A FAK INHIBITOR
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
IL279173A (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
IL280762A (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP3990448A4 (en) Heterocyclic compounds as inhibitors of kras g12c
AU2021403827A1 (en) N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
EP3856164A4 (en) MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
DK4055021T3 (en) HETEROCYCLIC RIP1 INHIBITOR COMPOUNDS
IL289594A (en) New heterocyclic monoacylglycerol lipase (magl) inhibitors
EP3870181A4 (en) CRYSTALLINE FORMS OF AN ALK2 INHIBITOR
PE20170705A1 (en) NEW COMPOUNDS AS RET INHIBITORS (REORGANIZED DURING TRANSFECTION)
IL289140A (en) Monitoring surface cleaning of medical surfaces using video streaming
IL288936A (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
MX2021010133A (en) CRYSTALLINE FORM OF 1-(1-OXO-1,2-DIHYDROISOQUINOLIN-5-IL)-5-(TRIFLUOROMETHYL)-N-(2-(TRIFLUOROMETHYL)PYRIDIN-4-IL)-1H-PYRAZOLE-4-CARBOX MONOHYDRATED AMIDE.
IL290289A (en) Amide hybridization of amphotericin b
DK3986401T3 (en) The peptidomimetic (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide for use in the treatment of amyotrophic lateral sclerosis
IL285763A (en) Solid polymorphs of the flana-binding compound and its hydrochloride salts
EP3996707A4 (en) CRYSTALLINE FORMS OF PLASMA KALLICREIN INHIBITORS
EP4241375A4 (en) SOLID-STATE TRANSFORMER CONTROL
HK40125946A (en) Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide
AR104935A1 (en) CRYSTAL FORMS OF A HISTONA DEACETILASA INHIBITOR
EP4069229A4 (en) SOLID STATE FORMS OF HDAC INHIBITOR
EP4743400A1 (en) CATHOD OF GROUP 14 - GROUP 1
EP3851438A4 (en) BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC AND APPLICATION OF THE SAME